ReviewCell proliferation2015
Epigenetic deregulations in chordoma.
Review in Cell proliferation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- CircRNAs in Immuno-Metabolic Reprogramming of Chordoma Cancer: Molecular Crosstalk and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.Journal of neuro-oncology · 2025Review
- A novel histone acetylation-associated gene signature with prognostic value in Ewing sarcoma.Discover oncology · 2024Article
- SIRT5 promote malignant advancement of chordoma by regulating the desuccinylation of c-myc.BMC cancer · 2024Article
- A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma.Frontiers in oncology · 2022Review
- Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.Frontiers in oncology · 2020Article
- Upregulation Of miR-149-3p Suppresses Spinal Chordoma Malignancy By Targeting Smad3.OncoTargets and therapy · 2019Article
- Clinicopathologic implications of CD8Cancer immunology, immunotherapy : CII · 2018Article
- Comprehensive analysis of mRNA-lncRNA co-expression profile revealing crucial role of imprinted gene cluster DLK1-MEG3 in chordoma.Oncotarget · 2017Article
- Aberrant DNA methylations in chondrosarcoma.Epigenomics · 2016Review
- Circulating epigenetic biomarkers in melanoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- MicroRNA-665 suppressed the invasion and metastasis of osteosarcoma by directly inhibiting RAB23.American journal of translational research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoma is a rare type of malignant bone tumour arising from remnant notochord and prognosis of patients with it remains poor as its molecular and genetic mechanisms are not well understood. Increasing evidence has demonstrated that epigenetic mechanisms (DNA methylation, histone modification and nucleosome remodelling), play a crucial role in the pathogenesis of many diseases. Aberrant epigenetic patterns are present in patients with chordoma, indicating a potential role for epigenetic mechanisms inthis malignancy. Furthermore, epigenetic alterations may provide novel biomarkers for diagnosis and prognosis as well as therapeutic targets for treatment. In this review, we discuss relevant epigenetic findings associated with chordoma, and their potential application for diagnosis, prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.